BLASUBCUTANEOUSSOLUTION2 Generics Approved
Approved
Sep 2017
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
FIASP PENFILL (insulin aspart injection) by Novo Nordisk. Approved for insulin analog [epc]. First approved in 2017.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FIASP PENFILL is a rapid-acting insulin aspart injection delivered via prefilled pen for subcutaneous administration. It is indicated for diabetes management in patients requiring insulin therapy. The drug works by stimulating peripheral glucose uptake and inhibiting hepatic glucose production, providing faster onset than standard insulin aspart.
$0.002BPart D
PeakStable
Product is in peak commercial phase with modest Part D spending; team focus is likely on market maintenance and device differentiation rather than growth expansion.
Mechanism of Action
Pharmacologic Class:
Insulin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
FIASP PENFILL shows minimal linked job activity, reflecting its niche position within the broader insulin portfolio dominated by FlexTouch. Career opportunities are concentrated in device differentiation, payer relations, and physician education roles rather than high-profile brand leadership.
Company
Worked on FIASP PENFILL at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.